Last reviewed · How we verify
Pembrolizumab/Vibostolimab Co-Formulation
Pembrolizumab/Vibostolimab Co-Formulation is a PD-1/PD-L1 inhibitor that works by blocking the PD-1/PD-L1 interaction, thereby enhancing the body's immune response against cancer cells.
Pembrolizumab/Vibostolimab Co-Formulation is a PD-1/PD-L1 inhibitor that works by blocking the PD-1/PD-L1 interaction, thereby enhancing the body's immune response against cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Pembrolizumab/Vibostolimab Co-Formulation |
|---|---|
| Also known as | MK-7684A |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This co-formulation combines pembrolizumab, a PD-1 inhibitor, with vibostolimab, a PD-L1 inhibitor. By blocking the PD-1/PD-L1 interaction, the immune system is able to recognize and attack cancer cells more effectively. This combination has shown promise in treating various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (PHASE3)
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (PHASE1, PHASE2)
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (PHASE3)
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)
- Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: